Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABP 206 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on ABP 206, a putative Opdivo (nivolumab) biosimilar (Oct 2023). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABP 206 | ABP206|ABP-206 | Limited information is currently available on ABP 206, a putative Opdivo (nivolumab) biosimilar (Oct 2023). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06054555 | Phase III | ABP 206 Nivolumab | A Study to Evaluate ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | Recruiting | USA | TUR | ROU | NLD | LTU | LBN | ITA | HUN | HRV | FRA | EST | ESP | DEU | CZE | CAN | ARG | 16 |